Literature DB >> 19581908

Controversies in the treatment of idiopathic membranous nephropathy.

Meryl Waldman1, Howard A Austin.   

Abstract

Optimum treatment of idiopathic membranous nephropathy is both controversial and challenging. The most extensively studied and frequently used immunosuppressive regimens for this disease comprise alkylating agents plus corticosteroids or ciclosporin. All of these treatment options have inherent problems: they are not effective in all patients, partial-rather than complete-remissions are common, adverse effects are worrisome, and relapses after treatment cessation remain problematic. Alternative immunosuppressive agents have been tested in an effort to overcome these unresolved issues. This paper reviews the available evidence regarding both established and new agents for the treatment of patients with idiopathic membranous nephropathy, with an emphasis on the results of the most recent clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19581908      PMCID: PMC2965515          DOI: 10.1038/nrneph.2009.101

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  90 in total

1.  Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies.

Authors:  Hanna Debiec; Vincent Guigonis; Béatrice Mougenot; Fabrice Decobert; Jean-Philippe Haymann; Albert Bensman; Georges Deschênes; Pierre M Ronco
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

2.  Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy.

Authors:  Momir Polenakovic; Ladislava Grcevska; Sonja Dzikova
Journal:  Nephrol Dial Transplant       Date:  2003-06       Impact factor: 5.992

Review 3.  Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy.

Authors:  Patrizia Passerini; Claudio Ponticelli
Journal:  Semin Nephrol       Date:  2003-07       Impact factor: 5.299

4.  Mycophenolate mofetil treatment for primary glomerular diseases.

Authors:  Michael J Choi; Joseph A Eustace; Luis F Gimenez; Mohamed G Atta; Paul J Scheel; Renuka Sothinathan; William A Briggs
Journal:  Kidney Int       Date:  2002-03       Impact factor: 10.612

5.  Cyclosporin A treatment for idiopathic membranous nephropathy.

Authors:  X Yao; H Chen; Q Wang; Z Tang; W Hu; G Yin; Z Liu; L Li
Journal:  Chin Med J (Engl)       Date:  2001-12       Impact factor: 2.628

6.  Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.

Authors:  A J Branten; J F Wetzels
Journal:  Clin Nephrol       Date:  2001-07       Impact factor: 0.975

7.  Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan.

Authors:  Hideo Shiiki; Takao Saito; Yoshiharu Nishitani; Tetsuya Mitarai; Noriaki Yorioka; Ashio Yoshimura; Hitoshi Yokoyama; Shinichi Nishi; Yasuhiko Tomino; Kiyoshi Kurokawa; Hideto Sakai
Journal:  Kidney Int       Date:  2004-04       Impact factor: 10.612

8.  Rituximab for idiopathic membranous nephropathy.

Authors:  Giuseppe Remuzzi; Carlos Chiurchiu; Mauro Abbate; Verusca Brusegan; Mario Bontempelli; Piero Ruggenenti
Journal:  Lancet       Date:  2002-09-21       Impact factor: 79.321

9.  Rituximab in idiopathic membranous nephropathy: a one-year prospective study.

Authors:  Piero Ruggenenti; Carlos Chiurchiu; Varusca Brusegan; Mauro Abbate; Annalisa Perna; Claudia Filippi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

10.  The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy.

Authors:  D S Goumenos; P Kalliakmani; S Tsakas; F Sotsiou; J G Vlachojannis
Journal:  Clin Nephrol       Date:  2004-01       Impact factor: 0.975

View more
  19 in total

1.  Murine membranous nephropathy: immunization with α3(IV) collagen fragment induces subepithelial immune complexes and FcγR-independent nephrotic syndrome.

Authors:  Jun-Jun Zhang; Mahdi Malekpour; Wentian Luo; Linna Ge; Florina Olaru; Xu-Ping Wang; Maimouna Bah; Yoshikazu Sado; Laurence Heidet; Sandra Kleinau; Agnes B Fogo; Dorin-Bogdan Borza
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

2.  Nephrotic syndrome: A new specific test for idiopathic membranous nephropathy.

Authors:  Hanna Debiec; Pierre Ronco
Journal:  Nat Rev Nephrol       Date:  2011-08-09       Impact factor: 28.314

Review 3.  Pathogenesis of membranous nephropathy: recent advances and future challenges.

Authors:  Pierre Ronco; Hanna Debiec
Journal:  Nat Rev Nephrol       Date:  2012-02-28       Impact factor: 28.314

Review 4.  Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis.

Authors:  Shou-Liang Hu; Dan Wang; Wen-Jun Gou; Qing-Feng Lei; Te-An Ma; Jun-Zhang Cheng
Journal:  J Nephrol       Date:  2014-02-06       Impact factor: 3.902

5.  Mouse models of membranous nephropathy: the road less travelled by.

Authors:  Dorin-Bogdan Borza; Jun-Jun Zhang; Laurence H Beck; Catherine Meyer-Schwesinger; Wentian Luo
Journal:  Am J Clin Exp Immunol       Date:  2013-06-15

6.  Phospholipase A2 receptor staining in pediatric idiopathic membranous glomerulopathy.

Authors:  L Nicholas Cossey; Patrick D Walker; Chris P Larsen
Journal:  Pediatr Nephrol       Date:  2013-08-02       Impact factor: 3.714

Review 7.  Immunopathogenesis of membranous nephropathy: an update.

Authors:  Hanna Debiec; Pierre Ronco
Journal:  Semin Immunopathol       Date:  2014-04-09       Impact factor: 9.623

Review 8.  Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.

Authors:  Thilo C von Groote; Gabrielle Williams; Eric H Au; Yizhi Chen; Anna T Mathew; Elisabeth M Hodson; David J Tunnicliffe
Journal:  Cochrane Database Syst Rev       Date:  2021-11-15

Review 9.  Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials.

Authors:  Yizhi Chen; Arrigo Schieppati; Guangyan Cai; Xiangmei Chen; Javier Zamora; Giovanni A Giuliano; Norbert Braun; Annalisa Perna
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-28       Impact factor: 8.237

10.  Antioxidants in kidney diseases: the impact of bardoxolone methyl.

Authors:  Jorge Rojas-Rivera; Alberto Ortiz; Jesus Egido
Journal:  Int J Nephrol       Date:  2012-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.